Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedicitumab plus camrelizumab for advanced or metastatic urothelial adenocarcinoma or squamous cell carcinoma
ChiCTR2200055403Phase 2Recruiting
- Sponsor
- The Third Medical Center of PLA General Hospital
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and camrelizumab in bladder adenocarcinoma and bladder squamous cell carcinoma, sponsored by The Third Medical Center of PLA General Hospital. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
disitamab vedotincamrelizumab
03
Conditions
bladder adenocarcinomabladder squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2200055403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055403.